Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein

International Journal of Molecular Medicine

Volumn 29, Issue 1, 2012, Pages 12-17

  Qiu, Feng ^a   Bi, Shengli ^a   Wang, Yue ^a   Guo, Minzhuo ^a   Yi, Yao ^a   Chen, Siyong ^a   Guo, Yu ^a   Shen, Liping ^a   Jia, Zhiyuan ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Fusion protein; Hepatitis C virus; Immune response

Indexed keywords

EPITOPE; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HYBRID PROTEIN; IMMUNOMODULATING AGENT; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; PLASMID VECTOR;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENETIC TRANSFECTION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; RECOMBINANT PLASMID; SPLEEN CELL; T LYMPHOCYTE; VIRAL CLEARANCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; RABBITS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VIRAL HEPATITIS VACCINES;

EID: 84855169747     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.801     Document Type: Article

References (23)

1. Zein CO and Zein NN: Advances in therapy for hepatitis C infection. Microbes Infect 4: 1237-1246, 2002. (Pubitemid 35435278)
2. Lauer GM and Walker BD: Hepatitis C virus infection. N Engl J Med 345: 41-52, 2001. (Pubitemid 32634271)
3. Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284: 450-456, 2000. (Pubitemid 30484478)
4. Allain JP, Stramer SL, Carneiro-Proietti AB, et al.: Transfusion- transmitted infectious diseases. Biologicals 37: 71-77, 2009.
5. Shin HR, Oh JK, Masuyer E, et al.: Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 101: 579-585, 2010.
6. Jia L, Yu J, Yang J, et al.: HCV antibody response and genotype distribution in different areas and races of China. Int J Biol Sci 5: 421-427, 2009.
7. Alves de Mattos A and Zambam de Mattos A: Treatment of HCV infection in patients with cirrhosis. Ann Hepatol 9 (Suppl 1): S80-S83, 2010.
8. Ueno Y, Sollano JD and Farrell GC: Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 24: 531-536, 2009.
9. Sanyal AJ, Yoon SK and Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15 (Suppl 4): S14-S22, 2010.
10. Bode JG, Brenndorfer ED and Haussinger D: Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol Chem 389: 1283-1298, 2008.
11. Sarrazin C and Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462, 2010.
12. Asselah T, Estrabaud E, Bieche I, et al.: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30: 1259-1269, 2010.
13. Houghton M and Abrignani S: Prospects for a vaccine against the hepatitis C virus. Nature 436: 961-966, 2005. (Pubitemid 41191672)
14. Gottwein JM and Bukh J: Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res 71: 51-133, 2008.
15. Houghton M: Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239: 99-108, 2011.
16. Wintermeyer P and Wands JR: Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol 42: 424-432, 2007. (Pubitemid 47050004)
17. Lin Y, Kwon T, Polo J, et al.: Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4 and 5. J Virol 82: 7492-7503, 2008. (Pubitemid 352031217)
18. Prentoe J, Jensen TB, Meuleman P, et al.: Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 85: 2224-2234, 2011.
19. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB and Baumert TF: Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8: 333-345, 2009.
20. Pujol FH and Devesa M: Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma. J Clin Gastroenterol 39: 611-618, 2005. (Pubitemid 41061268)
21. Houghton M: The long and winding road leading to the identification of the hepatitis C virus. J Hepatol 51: 939-948, 2009.
22. Burke KP and Cox AL: Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res 47: 216-227, 2010.
23. Bartosch B, Bukh J, Meunier JC, et al.: In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100: 14199-14204, 2003. (Pubitemid 37499214)